Chronic exposure to treatment with dopamine agonists, but no levodopa, suppresses striatal D 2 R availability, which may have relevance to output signaling to frontal lobes and the occurrence of executive deficits, but not dyskinesias.
Introduction
Postsynaptic striatal dopamine type-2 receptors (D 2 Rs) modulate the striatopallidal and the striatocortical signaling pathways in the basal ganglia output nuclei. In Parkinson's disease (PD), stimulation of these pathways is affected due to the progressive degeneration of dopaminergic neurons (Samii et al., 2004; Herz et al., 2015) , leading to alterations in synaptic dopamine levels and the development of motor symptoms (Pavese et al., 2006) , cognitive symptoms , and dyskinesias (Politis et al., 2014) . Although long-term changes in D 2 R availability may be also implicated (Antonini et al., 1997) , it is unclear how these changes are affected by the progression of the disease and the dopaminergic treatment in patients with PD.
[
11 C]raclopride PET is a selective marker and a valuable tool for investigating D 2 R availability in vivo (Laruelle et al., 2000) . [
11 C]raclopride PET studies in de novo PD patients have reported an increase in D 2 R availability in the putamen contralateral to the more affected limbs, while the D 2 R availability in the caudate remains intact (Rinne et al., 1993; Turjanski et al., 1997) . A combined PET study with [
18 F]fluoro-Ldopa (F-DOPA), a marker of pre-synaptic dopamine storage capacity, and [ 11 C]raclopride reported inverse correlations between reduced F-DOPA and increased post-synaptic D 2 R in denovo PD (Sawle et al., 1993) . Therefore, in early denovo PD, upregulation of post-synaptic D 2 R in the putamen could be a compensatory mechanism in response to depletion of pre-synaptic dopaminergic terminals and synaptic dopamine levels. However, as PD progresses D 2 R availability normalizes in the putamen, but availability in the caudate is reduced (Antonini et al., 1997; Turjanski et al., 1997; Brooks et al., 1992; Dentresangle et al., 1999) . As the disease
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progresses and increasing degeneration of nigrostriatal dopamine neurons occurs this compensatory mechanism fails; leading to decreased D 2 R availability in caudate.
Furthermore, after 3-5 years of levodopa treatment, [
11 C]raclopride binding is significant reduced in the putamen and caudate compared to baseline (Antonini et al., 1997) . These findings suggest that down-regulation of striatal D 2 R in PD may be induced by chronic dopaminergic treatment. Alterations in D 2 R function have been also suggested to play a role in mechanisms underlying dyskinesias in PD (Boyce et al., 1990; Graham et al., 1993 ).
Here we used [ 11 C]raclopride PET to explore the integrity of striatal D 2 R ligand binding and its relevance to the development of clinical symptoms and the chronic exposure to dopaminergic treatment in a group of patients with PD.
Materials and Methods
Participants
We studied 68 patients with idiopathic PD according to the UK Brain Bank clinical diagnostic criteria. All PD patients were receiving dopamine replacement therapy. To assess the effect of dopamine agonist treatment, PD patients were divided into two groups, those who were receiving dopamine agonists (n=46; either Ropinerole or Pramipexole, not in extended release) and patients who had never received treatment with dopamine agonists (n=22). Apart from levodopa and dopamine agonists, PD patients were not on any other medication with known action on dopamine receptors.
Twelve healthy individuals matched for age and gender, with no history of A C C E P T E D M A N U S C R I P T to levodopa as described previously (Politis et al., 2014; Politis et al., 2010) .
Scanning procedures
All subjects had [ 11 C]raclopride PET and 1.5-Tesla (T) volumetric MRI in an OFF medication condition after 18h withdrawal of dopaminergic medications. Long acting dopaminergic medications were withdrawn for 72h prior to the PET scan. PET imaging was performed at the Cyclotron Unit (Hammersmith Hospital) and [ 11 C]raclopride radiotracer was supplied by Hammersmith Imanet plc, London, UK.
All subjects were scanned using an ECAT HR + (CTI/Siemens 962) 3D PET tomography scanner, with 15.5 cm total axial field of view (FOV). This camera has a mean image transaxial resolution (3D mode) over a 10 cm radius FOV of 6.0+0.5 mm and an axial resolution of 5.0 + 0.8 mm (Brix et al., 1997) . All subjects were scanned following administration of [ 11 C]raclopride as an intravenous bolus, mean dose 250MBq; PET images were obtained as 20 time frames acquired over 60 minutes.
Volumetric T1-weighted MRI scans were acquired using a 1.5T MRI (Picker Eclipse,
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Picker International Inc., Highlands Heights, OH, USA). MRI was performed on the same day as the PET for co-registration of functional images.
The study received ethical approval from the Ethics Committee of Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals. All subjects gave informed written consent in accordance with the Declaration of Helsinki.
[ 11 C]raclopride PET image analysis
Movement correction
Head movement correction was carried out for all PET images using frame-by-frame realignment (Montgomery et al., 2006) with in-house software (c-wave) implemented in Matlab 8.2 (The MathWorks Inc). Non-attenuated corrected images were denoised using a level 2, order 64 Battle Lemarie wavelet filter (Turkheimer et al., 1999) followed by realignment using a mutual information algorithm (Studholme et al., 1997) . The first three frames were excluded and frame 10 was chosen as the reference frame due to good signal-to-noise ratio. Frames 4-20 of the original time series were resliced and reassembled into a movement-corrected dynamic scan. Decay-corrected time-activity curves were derived and compared to those without movement correction. The amount and timing of any movements were assessed graphically and compared with intrascan notes. Motion correction was applied to all PET data, however since patients were scanned off medication, the effect of head movement has to be considered when interpreting the findings.
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Region of interest analysis
Regions-of-interest (ROIs) were manually delineated on individual co-registered volumetric T1-weigthed MRI images and sampled on parametric PET images, using 
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border by the external capsule/claustrum, and the medial border by the lamina medullaris lateralis. For each subject ROIs were manually delineated in both hemispheres. To minimize possible partial volume effects, anatomical data from high resolution MRI was used to manually delineate specific ROIs ensuring the volume for each ROI was standardized so there was no significant difference in ROI volume across groups. Therefore, reducing the effects of partial volume difference between groups which could account for changes in binding potential.
MRI volumetric analysis
FreeSurfer's image analysis suite (version 6) was used to process individual MRI scans to derive measures of subcortical volumes using automated procedures previous described (Fischl et al., 2002) . Subcortical volumes were normalized for intracranial volume using validated methods within the FreeSufer toolkit (Buckner et al., 2004 ).
Statistics
Statistical analysis and graph illustrations were performed with SPSS (version 22) and 
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Volumetric analysis
FreeSurfer analysis revealed no volumetric difference in the left and right caudate and putamen between PD patients and healthy controls (p>0.10).
Effect of medication on D 2 R availability
PD patients on dopamine agonist treatment had no differences in terms of age, Figure 2A ). In comparisons to PD patients who never received treatment with dopamine agonists, PD patients on dopamine agonist treatment had 9.2% reduced D 2 R availability in the caudate (p<0.05) and 12.8% decreased in the putamen (p<0.05) (Figure 2A ). There were no differences in the relation between BP ND and specific dopamine agonists (ropinerole or pramiprexole).
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Effect of dyskinesias on D 2 R availability
We found a significant interaction between the presence of dyskinesias and (Antonini et al., 1994; Turjanski et al., 1997; Brooks et al., 1992; Dentresangle et al., 1999) . Our [ 11 C]raclopride PET findings suggest that with longer disease duration, D 2 R availability is reduced in the caudate, but not in the putamen.
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Chronic exposure to dopamine agonist treatment suppresses D 2 R availability in both the caudate and putamen. Dopamine agonists directly target D 2 Rs mimicking the effects of endogenous dopamine. Therefore, down-regulation could be the result of Brooks et al., 1990; Brooks et al., 1992; Dentresangle et al., 1999; Antonini et al., 1994 Brooks et al., 1990; Brooks et al., 1992; Dentresangle et al., 1999; Antonini et al., 1994) . , 1997) . Although it has been postulated that alterations in striatal D 2 Rs may be involved in the development of dyskinesias in PD (Boyce et al., 1990; Graham et al., 1993) , it is more likely that loss of dopamine terminals and priming with levodopa play a prominent role. Other non-dopaminergic systems such as the glutamatergic and the serotonergic may play a prominent role in the development of dyskinesias in PD (Niccolini et al., 2015; Politis et al., 2014) . Lines of evidence suggest that relatively preserved presynaptic serotonergic terminals in the basal ganglia mishandle synaptic levels of dopamine and contribute in the occurrence of dyskinesias in PD (Politis et al., 2014; Smith et al., 2015) . et al., 2000; Kaasinen et al., 2003; Politis et al., 2008) . Hopefully, future studies will help understand the relevance of extra-striatal D 2 R system in the development of nonmotor symptoms and the associations with exposure to dopaminergic treatment in patients with PD.
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A C C E P T E D M A N U S C R I P T (Brooks et al., 1990; Brooks et al., 1992; Leenders et al., 1992; Rinne et al., 1993; Antonini et al., 1994; Atonini et al., 1997; Turjanski et al., 1997; Dentresangle et al., 1999) and shows a linear caudate reduction and a non-linear reduction of D 2 R availability in the putamen as PD progresses. Also, the suppressing effect of chronic dopamine agonist treatment in striatal D 2 R availability in patients with PD. PD= Parkinson's disease; D 2 R = dopamine receptor type-2. 
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Highlights
 D 2 R in caudate and putamen are differentially affected in PD.
 Loss of D 2 R in caudate correlates with longer disease duration.
 Dopamine agonists treatment, but not levodopa, suppresses caudate and putamen D 2 Rs.
 No association between striatal D 2 R availability, levodopa treatment and dyskinesia.
